Bo Young Cho

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 6

Top Topics

Randomized Controlled Trial

Mesenchymal Stem Cells

Placebo Controlled

Top Venues

Cardiovascular diabetology

Diabetes, obesity & metabolism

This page only lists publications with an associated author ORCID identifier.

Publications

Young Sang Lyu, Sangmo Hong, Si Eun Lee, Bo Young Cho, Cheol Young Park
Efficacy and safety of enavogliflozin vs. dapagliflozin as add-on therapy in patients with type 2 diabetes mellitus based on renal function: a pooled analysis of two randomized controlled trials. Cardiovascular diabetology 23 (1) (2024)
Young Sang Lyu, Sangmo Hong, Si Eun Lee, Bo Young Cho, Cheol Young Park
Efficacy and safety of enavogliflozin vs. dapagliflozin as add-on therapy in patients with type 2 diabetes mellitus based on renal function: a pooled analysis of two randomized controlled trials. Cardiovascular diabetology 23 (1) (2024)
Young Sang Lyu, Sangmo Hong, Si Eun Lee, Bo Young Cho, Cheol Young Park
Efficacy and safety of enavogliflozin vs. dapagliflozin as add-on therapy in patients with type 2 diabetes mellitus based on renal function: a pooled analysis of two randomized controlled trials. Cardiovascular diabetology 23 (1) (2024)
Young Sang Lyu, Sangmo Hong, Si Eun Lee, Bo Young Cho, Cheol Young Park
Efficacy and safety of enavogliflozin vs. dapagliflozin as add-on therapy in patients with type 2 diabetes mellitus based on renal function: a pooled analysis of two randomized controlled trials. Cardiovascular diabetology 23 (1) (2024)
Young Sang Lyu, Sangmo Hong, Si Eun Lee, Bo Young Cho, Cheol Young Park
Efficacy and safety of enavogliflozin vs. dapagliflozin as add-on therapy in patients with type 2 diabetes mellitus based on renal function: a pooled analysis of two randomized controlled trials. Cardiovascular diabetology 23 (1) (2024)
Soo Heon Kwak, Kyung Ah Han, Kyung-Soo Kim, Jae Myung Yu, EunSook Kim, Jong Chul Won, Jun Goo Kang, Choon Hee Chung, Seungjoon Oh, Sung Hee Choi, Kyu Chang Won, Sin Gon Kim, Seung Ah Cho, Bo Young Cho, Kyong Soo Park
Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24-week, multicentre, randomized, double-blind, placebo-controlled, phase III trial. Diabetes, obesity & metabolism (2023)